Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Thoracic 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 10Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Mesothelioma 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Neoplasms, Unknown Primary 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Anus Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 32fludarabine phosphate 25Peripheral Blood Stem Cell Transplantation 25Busulfan 20Antilymphocyte Serum 19Tacrolimus 15Mycophenolic Acid 15Filgrastim 15Cyclosporine 15Methotrexate 14Melphalan 12Etoposide 12pembrolizumab 11Whole-Body Irradiation 10Radiotherapy 10Methylprednisolone 10Sirolimus 9Psychiatric Rehabilitation 8Nivolumab 8Bortezomib 8fludarabine 7Prednisone 7Flow Cytometry 7sargramostim 6romidepsin 6Vorinostat 6Gemcitabine 6Doxorubicin 6Cord Blood Stem Cell Transplantation 6aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × tislelizumab × Dermatologic × Clear all
NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Novartis

Phase 1 Terminated
60 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡